Budesonide inhalation - AstraZeneca

Drug Profile

Budesonide inhalation - AstraZeneca

Alternative Names: Rhinocort Aqua

Latest Information Update: 06 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Nasal polyps; Perennial allergic rhinitis; Rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 05 Dec 2016 Cilag completes the agreement with AstraZeneca to acquire budesonide inhalation (Rhinocort Aqua) outside USA
  • 07 Oct 2016 Cilag plans to acquire budesonide nasal (Rhinocort Aqua) outside the US in the fourth quarter of 2016
  • 17 Sep 2009 Launched for Rhinitis in Canada (Intranasal, 64μg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top